Medical World News® Behind the Science: Night Shift Work and the Resulting Effects on DNA Damage in the Development of Cancer

Video

CancerNetwork® sat down with Hans P.A. Van Dongen, PhD, Shobhan Gaddameedhi, PhD, and Jason McDermott, PhD, to discuss their research into how circadian disruptions may lead to changes in cancer-related genes.

A recent study published in the Journal of Pineal Research revealed new evidence showing why night shift workers are at increased risk of developing certain types of cancer. The study involved a controlled laboratory experiment that simulated night or day shift schedules in healthy volunteers. Findings suggested that night shift work disrupts natural rhythms in the activity of certain cancer-related genes, making night workers more vulnerable to DNA damage.

CancerNetwork sat down with key investigators on the study to discuss known risks associated with circadian disruption, methods of their research, effects of night shift work on DNA repair pathways, and the importance of these data.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News.

Reference

Koritala BSC, Porter KI, Arshad OA, et al. Night shift schedule causes circadian dysregulation of DNA repair genes and elevated DNA damage in humans. J Pineal Res. 2021;70(3):e12726. doi: 10.1111/jpi.12726

Recent Videos
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Related Content
The Potential for Improved Processes, Outcomes, and Economics of Health Care

The Potential for Improved Processes, Outcomes, and Economics of Health Care

Nora Janjan, MD, MPSA, MBA
February 21st 2025
Article

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Forecast on Eliminating Cancer Disparities Looks to Ethnic Enclave Research

Forecast on Eliminating Cancer Disparities Looks to Ethnic Enclave Research

Ariana Pelosci
February 18th 2025
Article

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor

FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor

Tim Cortese
February 14th 2025
Article

Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.

The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.

Program Evaluating TIDAL-01 in Solid Tumors Has Been Discontinued

Roman Fabbricatore
February 7th 2025
Article

The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.